1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-15.30%
Cash & equivalents declining -15.30% while Biotechnology shows 0.00% growth. Howard Marks would investigate if this cash drain is temporary or signals deeper issues.
No Data
No Data available this quarter, please select a different quarter.
-15.30%
Below half the Biotechnology median of 0.00% yoy growth. Jim Chanos might see inadequate liquidity buildup relative to peers. Verify free cash flow trends.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-15.91%
Below half the Biotechnology median of 0.00%. Jim Chanos would question if the company faces working capital strain.
-12.74%
PP&E growth below half of Biotechnology median of 0.00%. Jim Chanos would suspect potential underinvestment or strategic shift away from core assets.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.02%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos sees a red flag for intangible or questionable expansions in the balance sheet.
-1.64%
Below half the Biotechnology median of 0.00%. Jim Chanos sees a sharp divergence from peers, possibly a sign of strategic retreat or capital shortage.
No Data
No Data available this quarter, please select a different quarter.
-15.58%
Below half the Biotechnology median of 0.00%. Jim Chanos might see potential stagnation or distress vs. peers.
72.22%
Payables growth above 1.5x Biotechnology median of 0.00%. Jim Chanos might see a warning sign of stressed supplier payments.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-79.94%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects a potential short-term burden spike.
32.21%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects potential working capital strain.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
32.21%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects an alarming rise in overall leverage.
0.06%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects heavier share issuance than peers.
-3.27%
≥ 1.5x Biotechnology median of -2.10%. Joel Greenblatt sees stronger retained profit growth vs. peers.
0.51%
Above 1.5x Biotechnology median 0.00%. Jim Chanos suspects a red flag if these gains are highly volatile.
No Data
No Data available this quarter, please select a different quarter.
-24.85%
Below half Biotechnology median of 0.00%. Jim Chanos suspects slower net worth growth or losses vs. peers.
-15.58%
Below half Biotechnology median of 0.00%. Jim Chanos suspects a major slowdown or distress.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
15.30%
Above 1.5x Biotechnology median 0.00%. Jim Chanos sees a big jump in net debt. Potential leverage red flag.
